ZA200400194B - Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists. - Google Patents

Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists.

Info

Publication number
ZA200400194B
ZA200400194B ZA200400194A ZA200400194A ZA200400194B ZA 200400194 B ZA200400194 B ZA 200400194B ZA 200400194 A ZA200400194 A ZA 200400194A ZA 200400194 A ZA200400194 A ZA 200400194A ZA 200400194 B ZA200400194 B ZA 200400194B
Authority
ZA
South Africa
Prior art keywords
vla
antagonists
preparation
imidazolidine derivatives
novel imidazolidine
Prior art date
Application number
ZA200400194A
Other languages
English (en)
Inventor
Volkmar Wehner
Stefanie Flohr
Horst Blum
Hartmut Ruetten
Hans Ulrich Stilz
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ZA200400194B publication Critical patent/ZA200400194B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200400194A 2001-08-01 2004-01-12 Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists. ZA200400194B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10137595A DE10137595A1 (de) 2001-08-01 2001-08-01 Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
ZA200400194B true ZA200400194B (en) 2005-03-14

Family

ID=7693930

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200400194A ZA200400194B (en) 2001-08-01 2004-01-12 Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists.

Country Status (30)

Country Link
US (1) US6962937B2 (de)
EP (1) EP1414444B1 (de)
JP (1) JP4676697B2 (de)
KR (1) KR100910930B1 (de)
CN (1) CN1537000B (de)
AR (1) AR036349A1 (de)
AT (1) ATE391504T1 (de)
AU (1) AU2002328931B2 (de)
BR (1) BR0211535A (de)
CA (1) CA2455966C (de)
CO (1) CO5550452A2 (de)
DE (2) DE10137595A1 (de)
DK (1) DK1414444T3 (de)
ES (1) ES2301673T3 (de)
HK (1) HK1066166A1 (de)
HR (1) HRP20040108A2 (de)
HU (1) HUP0401406A3 (de)
IL (2) IL160093A0 (de)
MX (1) MXPA04000041A (de)
MY (1) MY133467A (de)
NO (1) NO326696B1 (de)
NZ (1) NZ530887A (de)
PE (1) PE20030348A1 (de)
PL (1) PL365396A1 (de)
PT (1) PT1414444E (de)
RS (1) RS6104A (de)
RU (1) RU2318815C2 (de)
TW (1) TWI325863B (de)
WO (1) WO2003011288A1 (de)
ZA (1) ZA200400194B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539744A4 (de) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-hydroxyamidderivate mit antibakterieller wirkung
EP2093218A1 (de) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkylsubstituierte Imidazolidinone
AU2009244863A1 (en) * 2008-05-05 2009-11-12 Winthrop University Hospital Method for improving cardiovascular risk profile of COX inhibitors
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (de)
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
WO1993013798A1 (en) 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
AU674302B2 (en) 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
AU3738597A (en) 1996-07-25 1998-02-20 Biogen, Inc. Molecular model for vla-4 inhibitors
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1027328B1 (de) 1997-10-31 2006-08-23 Aventis Pharma Limited Substituierte anilide
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR20010083081A (ko) 1998-06-30 2001-08-31 실버스타인 아써 에이. 염증성질환, 자가면역질환 및 호흡기질환을 치료하는데유용한 브이엘에이-4-의존성 세포 결합의 비-펩티딜 억제제
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TWI325863B (en) 2010-06-11
US20030109497A1 (en) 2003-06-12
MY133467A (en) 2007-11-30
PT1414444E (pt) 2008-05-27
KR20040020076A (ko) 2004-03-06
DK1414444T3 (da) 2008-08-04
MXPA04000041A (es) 2004-05-21
CA2455966C (en) 2011-09-20
JP4676697B2 (ja) 2011-04-27
CO5550452A2 (es) 2005-08-31
DE10137595A1 (de) 2003-02-13
PE20030348A1 (es) 2003-05-14
RU2318815C2 (ru) 2008-03-10
KR100910930B1 (ko) 2009-08-06
CA2455966A1 (en) 2003-02-13
EP1414444A1 (de) 2004-05-06
JP2005504033A (ja) 2005-02-10
NO20040426L (no) 2004-03-26
WO2003011288A1 (en) 2003-02-13
ES2301673T3 (es) 2008-07-01
CN1537000A (zh) 2004-10-13
AR036349A1 (es) 2004-09-01
HUP0401406A2 (hu) 2004-10-28
IL160093A0 (en) 2004-06-20
PL365396A1 (en) 2005-01-10
NZ530887A (en) 2005-09-30
HK1066166A1 (en) 2005-03-18
AU2002328931B2 (en) 2008-04-24
RU2004105966A (ru) 2005-06-27
DE60226032T2 (de) 2009-05-20
DE60226032D1 (de) 2008-05-21
BR0211535A (pt) 2004-07-13
US6962937B2 (en) 2005-11-08
ATE391504T1 (de) 2008-04-15
CN1537000B (zh) 2010-05-12
HRP20040108A2 (en) 2004-06-30
IL160093A (en) 2009-05-04
NO326696B1 (no) 2009-02-02
RS6104A (en) 2006-10-27
HUP0401406A3 (en) 2004-11-29
EP1414444B1 (de) 2008-04-09

Similar Documents

Publication Publication Date Title
TWI371450B (en) Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
ZA200107983B (en) New compounds, their preparation and use.
IL161881A (en) N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HK1061852A1 (en) 4,5-dihydro-ih-pyrazole derivatives having cb1-antagonistic activity
HUP0500983A2 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
ZA200104196B (en) Azepinoindole derivatives, the production and use thereof.
HUP0104917A3 (en) Azepinoindole derivatives, the production and use thereof
HK1050004A1 (en) Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands.
ZA200407794B (en) Novel biomaterials, their preparation and use.
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
ZA200204814B (en) Substituted phenyl-piperazine derivatives, their preparation and use.
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
SI1268522T1 (sl) Novi antagonisti lhrh, njihova priprava in uporaba kot zdravila
ZA996814B (en) Aluminosilicate compositions, preparation and use.
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
HUP0300222A3 (en) Novel lhrh-antagonists, production and use thereof as medicament
ZA200400194B (en) Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists.
MXPA03007634A (es) Derivados de imidazolidina, su preparacion, su uso y preparaciones farmaceuticas que los contienen.
MXPA03006162A (es) Derivados de mikanolida, su preparacion y sus usos terapeuticos.
ZA200109571B (en) Novel compounds, their use and preparation.
ZA200001747B (en) 3-Amino-3-arylpropan-1-ol derivatives, their preparation and use.
HUP0204084A3 (en) Novel heteroaryl derivatives, their preparation and use
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use